In congenital hypothyroidism, an initial L-thyroxine dose of 10–12 μg/kg/day is sufficient and sometimes excessive based on thyroid tests 1 month later
Abstract
Background: Current guidelines recommend an initial L-thyroxine (L-T4) dose of 10–15 μg/kg/day for the treatment of congenital hypothyroidism (CH). We analyzed our data for the treatment outcome at 1 month after we noted a frequent overtreatment even at the lower end of this dose range.
Methods: A 3-year chart review of 55 patients with confirmed CH was performed. The patients were divided to three groups based on L-T4 dose: Group 1 (6–9.9 μg/kg), Group 2 (10–11.9 μg/kg), and Group 3 (12–15 μg/kg). Overtreatment was defined as T4>16 μg/dL/free T4>2.3 ng/dL±thyroid-stimulating hormone (TSH) <0.5 μIU/L and undertreatment was defined as TSH>6 μIU/L at 1 month.
Results: At 1 month, 45.8%, 37.5%, and 16.6% in Group 1, 30%, 55%, and 15% in Group 2, and 0%, 75%, and 25% in Group 3 had target labs, overtreatment, and undertreatment, respectively.
Conclusions: An initial L-T4 dose of 10–11.9 μg/kg for TSH>100 μIU/L and 8–10 μg/kg for TSH<100 μIU/L at diagnosis met and often exceeded the target thyroid levels at 1 month. More frequent overtreatment was seen when >12 μg/kg was given.
©2012 by Walter de Gruyter Berlin Boston
Artikel in diesem Heft
- Masthead
- Masthead
- Editorial
- Growth hormone mortality: will history repeat itself?
- Review articles
- Interval training and the GH-IGF-I axis – a new look into an old training regimen
- Bone health in children and adolescent with Turner syndrome
- Metabolic alterations in pregnant women: gestational diabetes
- Short communication
- A method to determine the likelihood of transition to puberty in a heterogeneous prepubertal age group
- Images in pediatric endocrinology
- Hypopituitarism occurring in neonatal sepsis
- Original articles
- In congenital hypothyroidism, an initial L-thyroxine dose of 10–12 μg/kg/day is sufficient and sometimes excessive based on thyroid tests 1 month later
- TSH suppression after intravenous glucocorticosteroid administration in preterm infants
- Frequency of subclinical hypothyroidism in 5- to 15-year-old children with migraine headache
- Higher dose of methimazole causes frequent adverse effects in the management of Graves’ disease in children and adolescents
- Water deprivation test in children with polyuria
- Training increases anabolic response and reduces inflammatory response to a single practice in elite male adolescent volleyball players
- Positive effects of zinc supplementation on growth, GH, IGF1, and IGFBP3 in eutrophic children
- A novel intronic mutation in SHOX causes short stature by disrupting a splice acceptor site: direct demonstration of aberrant splicing by expression of a minigene in HEK-293T cells
- Increased growth hormone receptor (GHR) degradation due to over-expression of cytokine inducible SH2 domain-containing protein (CIS) as a cause of GH transduction defect (GHTD)
- Japanese growth prediction model for prepubertal children with growth hormone deficiency
- Clinical features and management of diabetic ketoacidosis in different age groups of children: children less than 5 years of age are at higher risk of metabolic decompensation
- Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease
- Serum ischemia-modified albumin level and its association with cardiovascular risk factors in obese children and adolescents
- Obesity, insulin resistance, and the risk of an elevated alanine aminotransferase activity in the Korean adolescent population
- Leptin and IGF-I/II during the first weeks of life determine body composition at 2 years in infants born with very low birth weight
- Analysis of the β-glucocerebrosidase gene in Turkish Gaucher disease patients: mutation profile and description of a novel mutant allele
- Mutational analysis of the GYS2 gene in patients diagnosed with ketotic hypoglycaemia
- Low bone status in Indian growth hormone-deficient children
- Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH)
- Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features
- Recurrent hypoglycemia due to growth hormone deficiency in an infant with Turner syndrome
- Patient reports
- Intrathyroidal ectopic thymic tissue may mimic thyroid cancer: a case report
- Hypercortisolism and hypothyroidism in an infant with Smith-Lemli-Opitz syndrome
- Peripheral precocious puberty due to inadvertent exposure to testosterone: case report and review of the literature
- Absent phallus: issues in management
- A case of recurrent labial adhesions in a 15-month-old child with asymptomatic non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Response to growth hormone treatment in a patient with 18p-syndrome
- Hypodipsic hypernatremia leading to reversible renal failure following surgery for craniopharyngioma
- Transient isolated marked elevation of midregion parathyroid hormone fragments in an infant
- A novel splice site mutation of the beta subunit gene of epithelial sodium channel (ENaC) in one Turkish patient with a systemic form of pseudohypoaldosteronism type 1
- Letters to the editor
- What is the priority in nutritional rickets: prevention or therapy?
- The true relation between vitamin D and insulin sensitivity: is it easy to establish?
- Birth asphyxia and hypothermia therapy: is survivin the orchestrator of recovery?
- Delayed cord clamping in intrauterine growth restriction (IUGR) neonates: is there a need to establish clinical cut-off score for inclusion?
Artikel in diesem Heft
- Masthead
- Masthead
- Editorial
- Growth hormone mortality: will history repeat itself?
- Review articles
- Interval training and the GH-IGF-I axis – a new look into an old training regimen
- Bone health in children and adolescent with Turner syndrome
- Metabolic alterations in pregnant women: gestational diabetes
- Short communication
- A method to determine the likelihood of transition to puberty in a heterogeneous prepubertal age group
- Images in pediatric endocrinology
- Hypopituitarism occurring in neonatal sepsis
- Original articles
- In congenital hypothyroidism, an initial L-thyroxine dose of 10–12 μg/kg/day is sufficient and sometimes excessive based on thyroid tests 1 month later
- TSH suppression after intravenous glucocorticosteroid administration in preterm infants
- Frequency of subclinical hypothyroidism in 5- to 15-year-old children with migraine headache
- Higher dose of methimazole causes frequent adverse effects in the management of Graves’ disease in children and adolescents
- Water deprivation test in children with polyuria
- Training increases anabolic response and reduces inflammatory response to a single practice in elite male adolescent volleyball players
- Positive effects of zinc supplementation on growth, GH, IGF1, and IGFBP3 in eutrophic children
- A novel intronic mutation in SHOX causes short stature by disrupting a splice acceptor site: direct demonstration of aberrant splicing by expression of a minigene in HEK-293T cells
- Increased growth hormone receptor (GHR) degradation due to over-expression of cytokine inducible SH2 domain-containing protein (CIS) as a cause of GH transduction defect (GHTD)
- Japanese growth prediction model for prepubertal children with growth hormone deficiency
- Clinical features and management of diabetic ketoacidosis in different age groups of children: children less than 5 years of age are at higher risk of metabolic decompensation
- Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease
- Serum ischemia-modified albumin level and its association with cardiovascular risk factors in obese children and adolescents
- Obesity, insulin resistance, and the risk of an elevated alanine aminotransferase activity in the Korean adolescent population
- Leptin and IGF-I/II during the first weeks of life determine body composition at 2 years in infants born with very low birth weight
- Analysis of the β-glucocerebrosidase gene in Turkish Gaucher disease patients: mutation profile and description of a novel mutant allele
- Mutational analysis of the GYS2 gene in patients diagnosed with ketotic hypoglycaemia
- Low bone status in Indian growth hormone-deficient children
- Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH)
- Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features
- Recurrent hypoglycemia due to growth hormone deficiency in an infant with Turner syndrome
- Patient reports
- Intrathyroidal ectopic thymic tissue may mimic thyroid cancer: a case report
- Hypercortisolism and hypothyroidism in an infant with Smith-Lemli-Opitz syndrome
- Peripheral precocious puberty due to inadvertent exposure to testosterone: case report and review of the literature
- Absent phallus: issues in management
- A case of recurrent labial adhesions in a 15-month-old child with asymptomatic non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Response to growth hormone treatment in a patient with 18p-syndrome
- Hypodipsic hypernatremia leading to reversible renal failure following surgery for craniopharyngioma
- Transient isolated marked elevation of midregion parathyroid hormone fragments in an infant
- A novel splice site mutation of the beta subunit gene of epithelial sodium channel (ENaC) in one Turkish patient with a systemic form of pseudohypoaldosteronism type 1
- Letters to the editor
- What is the priority in nutritional rickets: prevention or therapy?
- The true relation between vitamin D and insulin sensitivity: is it easy to establish?
- Birth asphyxia and hypothermia therapy: is survivin the orchestrator of recovery?
- Delayed cord clamping in intrauterine growth restriction (IUGR) neonates: is there a need to establish clinical cut-off score for inclusion?